Castle Biosciences Reports Fourth Quarter and Full-Year 2021 Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/27/2026
- Wall Street ends higher as investors buy AI stocks; Microsoft rallies
- Stock action shows confidence in central banks: BofA’s Hartnett
- Oil prices slide about 2% as US, Iran explore path out of war
- Why stocks held up despite rising yields and $100 oil? These 2 words explain it
- Barclays asks if equity markets are nearing the boiling point
- White House blocks CNN from Air Force One trip, Washington Post reports
- Merck and Daiichi Sankyo withdraw lung cancer drug application
- Exclusive-SK Hynix's Solidigm weighs IPO that could value the unit at up to $150 billion, sources say
- Fox Factory sells Marucci Sports for $225M, cuts debt
- Wall Street ends higher as investors buy AI stocks; Microsoft rallies
Castle Biosciences Inc. (CSTL) Tops Q4 EPS by 22c
February 28, 2022 4:14 PM ESTCastle Biosciences Inc. (NASDAQ: CSTL) reported Q4 EPS of ($0.25), $0.22 better than the analyst estimate of ($0.47). Revenue for the quarter came in at $25 million versus the consensus estimate of $23.73 million.
GUIDANCE:
Castle Biosciences Inc. sees FY2022 revenue of $115-120... More
